Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Walker

Pulmonary Disease Anderson, SC Medical Doctor

NPI 1700889904 CMS profile 259117

2000 East Greenville St, Suite 1100, Anderson, SC 29621

Open in the dashboard

General payments

$3,287

202 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Walker of Anderson, SC is reported in the CMS Open Payments database as having received $3,287 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $86 8
2024 General $507 29
2023 General $518 27
2022 General $262 14
2021 General $493 29
2020 General $682 42
2019 General $739 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Walker
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to William Walker were reported at $86. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year William Walker Pulmonary Disease median Middle half National median
2019 $739 $377 $109–$1,340 $163
2020 $682 $230 $56–$907 $114
2021 $493 $269 $68–$1,072 $132
2022 $262 $390 $100–$1,457 $149
2023 $518 $419 $114–$1,659 $160
2024 $507 $476 $123–$1,818 $164
2025 $86 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $520 37 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $419 25 payments
  3. AstraZeneca Pharmaceuticals LP $391 23 payments
  4. Electromed, Inc. $250 24 payments
  5. Insmed, Inc. $202 14 payments
  6. Merck Sharp & Dohme Corporation $169 10 payments
  7. United Therapeutics Corporation $135 6 payments
  8. Pharming Healthcare, Inc. $92 4 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $90 4 payments
  10. Actelion Pharmaceuticals US, Inc. $85 4 payments
  11. Other $933 51 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,237 198 payments
  2. Education $50 4 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $326 21 payments
  2. SMARTVEST $233 22 payments
  3. OFEV $224 14 payments
  4. Arikayce $202 14 payments
  5. ZERBAXA $118 8 payments
  6. GLASSIA $108 5 payments
  7. STIOLTO RESPIMAT $96 5 payments
  8. ORENITRAM $94 4 payments
  9. RUCONEST $92 4 payments
  10. UPTRAVI $85 4 payments
  11. Other $2,074 121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 33 drugs

Part D claims

1,099

Median for Pulmonary Disease: 936

Drug cost

$549,116

Median for Pulmonary Disease: $487,987

Branded share of claims

62.1%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Arikayce Amikacin Liposomal/Neb.Accessr Brand 16 $242,719
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 181 $134,660
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 67 $52,905
Breo Ellipta Fluticasone/Vilanterol Brand 47 $29,916
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 40 $26,652
Combivent Respimat Ipratropium/Albuterol Sulfate Brand 21 $15,608
Symbicort Budesonide/Formoterol Fumarate Brand 47 $15,089
Eliquis Apixaban Brand 20 $12,581
Dulera Mometasone/Formoterol Brand 18 $6,361
Albuterol Sulfate Hfa Albuterol Sulfate Brand 149 $5,146

The 10 drugs with the highest cost, of 33 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$53,332

Medicare's payments for the services billed

Medicare patients

228

Average age 77

Services billed

776

95 women, 133 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 65%
Ischemic heart disease 50%
Arthritis 50%
Heart failure 45%
Chronic kidney disease 43%
Diabetes 37%
Atrial fibrillation 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
  • GlaxoSmithKline, LLC. $72
$72 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $66
$66 — —
GLASSIA
  • Takeda Pharmaceuticals U.S.A., Inc. $51
$51 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $36
$36 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $31
$31 181 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record